Compare Logindo Samudramakmur Tbk. (LEAD) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logindo Samudramakmur Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Logindo Samudramakmur Tbk. trades at Rp112 (market cap 643.76B, 26.74M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Logindo Samudramakmur Tbk. is far larger — about 6.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| LEAD | SCPI | |
|---|---|---|
Market Cap | 643.76B | 104.4B |
Volume | 26.74M | — |
Lot | 267.43K | — |
Turnover | 2.9B | — |
Average Price | 108.62 | — |
Value | 2.9B | — |
Indicative Equilibrium Price | 112 | — |
Indicative Equilibrium Volume | 7.92K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logindo Samudramakmur Tbk.
PT Logindo Samudramakmur Tbk (the Company) is domiciled and was established in Jakarta, Indonesia based on Notarial Deed No. 55 of Nurul Hidajati Handoko, SH., Public Notary in Jakarta dated August 23, 1995. The company currently owns and operates a fleet of 58 offshore support with various types and functions. The company has a portfolio of customers ranging from mining oil and gas local to multinational.
Read more on LEAD →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
